
Patient Outreach Guide for Hemophilia and Other Bleeding Disorders – Arabic
This guide helps national hemophilia organizations plan and carry out an outreach campaign to identify people with hemophilia or other
Year: 2021
Language: Arabic
This resource is also available in: الإنجليزية الفرنسية الروسية الأسبانية
Format: Video
In this session from the Global Policy and Access Summit, Mukesh Garodia, Brian O’Mahony, Yuri Zhulyov, Margarita Elizabeth Garcia Gonzalez and Brian Fitzgerald give an overview of various procurement models for hemophilia and other inherited bleeding disorders therapeutic products, present key principles in setting up an efficient national procurement mechanism and highlight the importance of multi-stakeholder involvement in decision-making. Case studies from Russia, Ireland and Central America will be presented to offer insight on patient organization, government, and regional procurement agency perspectives.
This WFH session was originally presented in English.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.

This guide helps national hemophilia organizations plan and carry out an outreach campaign to identify people with hemophilia or other

Also Available In: Japanese A national tender system is a cost-effective system for the purchase of products or services, such

Also Available In: Japanese Patient registries are crucial for monitoring trends in health, allocating resources, organizing and tracking distribution of

Having a national patient registry means being able to answer fundamental questions about the hemophilia population within a given country.